Literature DB >> 2280889

Non-competitive N-methyl-D-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons.

E D French1, A Ceci.   

Abstract

The response of ventral tegmental (VTA) A10 dopamine neurons to a series of compounds covering the spectrum from high-affinity phencyclidine receptor ligands (MK-801, PCP) to high-affinity sigma-receptor ligands [+)-pentazocine, DTG) was measured using single-unit extracellular recording techniques in the rat. Dose-response comparisons revealed that MK-801 was 3, 6, 19 and 119 times more potent at activating A10 neurons than PCP, (+)-SKF-10,047, ketamine and (+)-pentazocine, respectively. DTG (1,3-di-o-tolylguanidine), the most selective sigma-ligand, and U50,488H, a kappa-opiate, failed to produce any stimulation of firing. Also, pretreatment with haloperidol, a potent sigma-receptor ligand, did not prevent MK-801-induced excitations. Thus, the activation of the A10-mesolimbic-mesocortical dopamine pathways by PCP, PCP-like drugs and sigma-psychotomimetics is mediated by the PCP receptor, not the haloperidol-sensitive sigma-receptor, with potencies directly correlated to their activity as non-competitive N-methyl-D-aspartate (NMDA) antagonists.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2280889     DOI: 10.1016/0304-3940(90)90823-r

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  34 in total

1.  Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats.

Authors:  D C Hoffman
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

Authors:  R Spanagel; A Herz; T S Shippenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

3.  Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats.

Authors:  M Bubser; T Tzschentke; W Hauber
Journal:  J Neural Transm Gen Sect       Date:  1995

4.  Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain.

Authors:  T Kobayashi; K Matsuno; M Murai; S Mita
Journal:  Neurochem Res       Date:  1997-09       Impact factor: 3.996

5.  Similar ameliorating effects of benzomorphans and 5-HT2 antagonists on drug-induced impairment of passive avoidance response in mice: comparison with acetylcholinesterase inhibitors.

Authors:  K Matsuno; T Senda; K Matsunaga; S Mita; H Kaneto
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801.

Authors:  D C Hoffman; H Donovan; J V Cassella
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats.

Authors:  K Wedzony; K Gołembiowska; M Zazula
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

8.  Phencyclidine-induced potentiation of brain stimulation reward: acute effects are not altered by repeated administration.

Authors:  W A Carlezon; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity.

Authors:  Pauline Belujon; Anthony A Grace
Journal:  Biol Psychiatry       Date:  2014-05-06       Impact factor: 13.382

10.  Selective reduction of N-methyl-D-aspartate-evoked responses by 1,3-di(2-tolyl)guanidine in mouse and rat cultured hippocampal pyramidal neurones.

Authors:  E J Fletcher; J Church; K Abdel-Hamid; J F MacDonald
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.